CERT Certara, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$6.85

Period return

-3.26 (-32.25%)

Volume

2.6M

2026-07-21O $6.81 H $6.99 L $6.76 C $6.85MA5 $7.01MA20 $6.58MA60 $5.88MA120 $6.25

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.01%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 13.LowHOLD2 months ago
Craig-Hallum: Hold
US analyst rating / recommendation change.
2026. 05. 13.LowHOLD2 months ago
BMO Capital: Market Perform
US analyst rating / recommendation change.
2026. 05. 12.LowHOLD2 months ago
Barclays: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 12.LowBUY2 months ago
Stephens & Co.: Overweight
US analyst rating / recommendation change.
2026. 05. 12.LowHOLD2 months ago
Morgan Stanley: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 12.LowHOLD2 months ago
Baird: Neutral
US analyst rating / recommendation change.
2026. 04. 13.LowBUY3 months ago
Keybanc: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $7.62 · 11 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$0.09	—	—	$99.49M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.03	—	—	$106M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.12	—	—	$284.79M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.11	—	—	$189.97M	Reported

Certara, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Craig-Hallum	—	Maintain	Hold → Hold	—	Craig-Hallum: Hold
2026. 05. 13.	BMO Capital	—	Maintain	Market Perform → Market Perform	—	BMO Capital: Market Perform
2026. 05. 12.	Barclays	—	Maintain	Equal-Weight → Equal-Weight	—	Barclays: Equal-Weight
2026. 05. 12.	Stephens & Co.	—	Maintain	Overweight → Overweight	—	Stephens & Co.: Overweight
2026. 05. 12.	Morgan Stanley	—	Maintain	Equal-Weight → Equal-Weight	—	Morgan Stanley: Equal-Weight
2026. 05. 12.	Baird	—	Maintain	Neutral → Neutral	—	Baird: Neutral

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	1,118,967	$6.38M	0.01%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	220,587	$1.94M	0.00%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	62,733	$357.58K	0.00%	—	New position